The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Metal complexes in cancer therapy – an update from drug design perspective
Open accessAbstract
In the past, metal-based compounds were widely used in the treatment of disease conditions, but the lack of clear distinction between the therapeutic and toxic doses was a major challenge. With the discovery of cisplatin by Barnett Rosenberg in 1960, a milestone in the history of metal-based compounds used in the treatment of cancers was witnessed. This forms the foundation for the modern era of the metal-based anticancer drugs. Platinum drugs, such as cisplatin, carboplatin and oxaliplatin, are the mainstay of the metal-based compounds in the treatment of cancer, but the delay in the therapeutic accomplishment of other metal-based compounds hampered the progress of research in this field. Recently, however, there has been an upsurge of activities relying on the structural information, aimed at improving and developing other forms of metal-based compounds and nonclassical platinum complexes whose mechanism of action is distinct from known drugs such as cisplatin. In line with this, many more metal-based compounds have been synthesized by redesigning the existing chemical structure through ligand substitution or building the entire new compound with enhanced safety and cytotoxic profile. However, because of increased emphasis on the clinical relevance of metal-based complexes, a few of these drugs are currently on clinical trial and many more are awaiting ethical approval to join the trial. In this review, we seek to give an overview of previous reviews on the cytotoxic effect of metal-based complexes while focusing more on newly designed metal-based complexes and their cytotoxic effect on the cancer cell lines, as well as on new approach to metal-based drug design and molecular target in cancer therapy. We are optimistic that the concept of selective targeting remains the hope of the future in developing therapeutics that would selectively target cancer cells and leave healthy cells unharmed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Advances in Copper Complexes as Anticancer Agents
Santini, C., Pellei, M., Gandin, V., Porchia, M., Tisato, F., & Marzano, C. (2014) · Chemical Reviews · doi:10.1021/cr400135x · Cited by 1,790
Florea, A.-M., & Büsselberg, D. (2011) · Cancers · doi:10.3390/cancers3011351 · Cited by 1,759
Hentze, M. W., Muckenthaler, M. U., & Andrews, N. C. (2004) · Cell · doi:10.1016/s0092-8674(04)00343-5 · Cited by 1,736
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
New trends for metal complexes with anticancer activity
Bruijnincx, P. C., & Sadler, P. J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.11.013 · Cited by 1,306
Elevated copper and oxidative stress in cancer cells as a target for cancer treatment
Gupte, A., & Mumper, R. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.07.004 · Cited by 1,036
Folate and DNA Methylation: A Review of Molecular Mechanisms and the Evidence for Folate's Role
Crider, K. S., Yang, T. P., Berry, R. J., & Bailey, L. B. (2012) · Advances in Nutrition · doi:10.3945/an.111.000992 · Cited by 1,015
Application of Metal Coordination Chemistry To Explore and Manipulate Cell Biology
Haas, K. L., & Franz, K. J. (2009) · Chemical Reviews · doi:10.1021/cr900134a · Cited by 984
Ji, H., Li, X., & Zhang, H. (2009) · EMBO reports · doi:10.1038/embor.2009.12 · Cited by 636
Chemical biology of anticancer gold(iii) and gold(i) complexes
Zou, T., Lum, C. T., Lok, C.-N., Zhang, J.-J., & Che, C.-M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00132c · Cited by 628
Redox compartmentalization in eukaryotic cells
Go, Y.-M., & Jones, D. P. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.01.011 · Cited by 626
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
Bindoli, A., Rigobello, M. P., Scutari, G., Gabbiani, C., Casini, A., & Messori, L. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.026 · Cited by 595
Ruthenium Complexes as Anticancer Agents
Kostova, I. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776360941 · Cited by 566
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
Arredondo, M., & Núñez, M. T. (2005) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.07.010 · Cited by 550
Encyclopedia of Metalloproteins
(2013) · Springer eBooks · doi:10.1007/978-1-4614-1533-6 · Cited by 531
Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
Utilizing the folate receptor for active targeting of cancer nanotherapeutics
Zwicke, G. L., Ali Mansoori, G., & Jeffery, C. J. (2012) · Nano Reviews · doi:10.3402/nano.v3i0.18496 · Cited by 458
Mouriño, V., Cattalini, J. P., & Boccaccini, A. R. (2012) · Journal of The Royal Society Interface · doi:10.1098/rsif.2011.0611 · Cited by 441
Copper and Its Complexes in Medicine: A Biochemical Approach
Iakovidis, I., Delimaris, I., & Piperakis, S. M. (2011) · Molecular Biology International · doi:10.4061/2011/594529 · Cited by 336
Metal-based drugs that break the rules
Allardyce, C. S., & Dyson, P. J. (2016) · Dalton Transactions · doi:10.1039/c5dt03919c · Cited by 308
The state-of-play and future of platinum drugs
Apps, M. G., Choi, E. H. Y., & Wheate, N. J. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0237 · Cited by 256
Liu, D., Poon, C., Lu, K., He, C., & Lin, W. (2014) · Nature Communications · doi:10.1038/ncomms5182 · Cited by 251
Copper homeostasis in eukaryotes: Teetering on a tightrope
Balamurugan, K., & Schaffner, W. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.05.001 · Cited by 249
Bertrand, B., Stefan, L., Pirrotta, M., Monchaud, D., Bodio, E., Richard, P., Le Gendre, P., Warmerdam, E., de Jager, M. H., Groothuis, G. M. M., et al. (2014) · Inorganic Chemistry · doi:10.1021/ic403011h · Cited by 245
Is Cancer a Metabolic Disease?
Coller, H. A. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.07.035 · Cited by 229
Monofunctional and Higher-Valent Platinum Anticancer Agents
Johnstone, T. C., Wilson, J. J., & Lippard, S. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400538c · Cited by 223
Linking the future of anticancer metal-complexes to the therapy of tumour metastases
Bergamo, A., & Sava, G. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00134j · Cited by 219
New strategies to deliver anticancer drugs to brain tumors
Laquintana, V., Trapani, A., Denora, N., Wang, F., Gallo, J. M., & Trapani, G. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903167942 · Cited by 214
Thioredoxin and Cancer: A Role for Thioredoxin in all States of Tumor Oxygenation
Karlenius, T. C., & Tonissen, K. F. (2010) · Cancers · doi:10.3390/cancers2020209 · Cited by 209
Lian, W.-J., Wang, X.-T., Xie, C.-Z., Tian, H., Song, X.-Q., Pan, H.-T., Qiao, X., & Xu, J.-Y. (2016) · Dalton Transactions · doi:10.1039/c6dt00461j · Cited by 192
Development of copper based drugs, radiopharmaceuticals and medical materials
Szymański, P., Frączek, T., Markowicz, M., & Mikiciuk-Olasik, E. (2012) · BioMetals · doi:10.1007/s10534-012-9578-y · Cited by 183
Hearn, J. M., Romero-Canelón, I., Qamar, B., Liu, Z., Hands-Portman, I., & Sadler, P. J. (2013) · ACS Chemical Biology · doi:10.1021/cb400070a · Cited by 166
Peptide-Based Treatment: A Promising Cancer Therapy
Xiao, Y.-F., Jie, M.-M., Li, B.-S., Hu, C.-J., Xie, R., Tang, B., & Yang, S.-M. (2015) · Journal of Immunology Research · doi:10.1155/2015/761820 · Cited by 163
Platinum anticancer drugs. From serendipity to rational design
Monneret, C. (2011) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2011.10.001 · Cited by 161
Patra, M., Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201510551 · Cited by 160
Chemotherapy advances in small-cell lung cancer.
Chan, B. A., & Coward, J. I. G. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.07.43 · Cited by 155
Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes
Díaz, M., & Vivas‐Mejía, P. E. (2013) · Pharmaceuticals · doi:10.3390/ph6111361 · Cited by 154
Satraplatin: leading the new generation of oral platinum agents
Bhargava, A., & Vaishampayan, U. N. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903362437 · Cited by 149
Babak, M. V., Meier, S. M., Huber, K., Reynisson, J., Legin, A. A., Jakupec, M. A., Roller, A., Stukalov, A., Gridling, M., Bennett, K. L., et al. (2015) · Chemical Science · doi:10.1039/c4sc03905j · Cited by 141
Millett, A. J., Habtemariam, A., Romero‐Canelón, I., Clarkson, G. J., & Sadler, P. J. (2015) · Organometallics · doi:10.1021/acs.organomet.5b00097 · Cited by 135
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
Weiss, A., Ding, X., B, J. R. V. B., Wong, I., Wong, T. J., Berndsen, R. H., Dormond, O., Dallinga, M. G., Shen, L., Schlingemann, R. O., et al. (2015) · Angiogenesis · doi:10.1007/s10456-015-9462-9 · Cited by 124
Gold complexes as prospective metal-based anticancer drugs.
Milacic, V., Fregona, D., & Dou, Q. P. (2008) · PubMed · doi:10.14670/hh-23.101 · Cited by 119
New-Generation Platinum Agents for Solid Tumors
Shah, N. A., & Dizon, D. S. (2009) · Future Oncology · doi:10.2217/14796694.5.1.33 · Cited by 114
The metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer
Capper, C. P., Rae, J. M., & Auchus, R. J. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0259-0 · Cited by 89
Florindo, P. R., Pereira, D. M., Borralho, P. M., Rodrigues, C. M. P., Piedade, M. F. M., & Fernandes, A. C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00403 · Cited by 84
Villarreal, W., Colina–Vegas, L., de Oliveira, C. R., Tenorio, J. C., Ellena, J., Gozzo, F. C., Cominetti, M. R., Ferreira, A. G., Ferreira, M. A. B., Navarro, M., et al. (2015) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.5b01647 · Cited by 81
Zhang, J.-J., Muenzner, J. K., el Maaty, M. A. A., Karge, B., Schobert, R., Wölfl, S., & Ott, I. (2016) · Dalton Transactions · doi:10.1039/c6dt02025a · Cited by 78
Maroto-Díaz, M., Elie, B. T., Gómez‐Sal, P., Pérez‐Serrano, J., Gómez, R., Contel, M., & de la Mata, F. J. (2016) · Dalton Transactions · doi:10.1039/c6dt00465b · Cited by 77
Kalinowska‐Lis, U., Felczak, A., Chęcińska, L., Szabłowska‐Gadomska, I., Patyna, E., Małecki, M., Lisowska, K., & Ochocki, J. (2016) · Molecules · doi:10.3390/molecules21020087 · Cited by 73
Fernández‐Gallardo, J., Elie, B. T., Sulzmaier, F. J., Sanaú, M., Ramos, J. W., & Contel, M. (2014) · Organometallics · doi:10.1021/om500965k · Cited by 68
Radiosensitisation of human colorectal cancer cells by ruthenium(II) arene anticancer complexes
Carter, R., Westhorpe, A., Romero, M., Habtemariam, A., Gallevo, C., Bark, Y., Menezes, N., Sadler, P. J., & Sharma, R. (2016) · Scientific Reports · doi:10.1038/srep20596 · Cited by 63
Copper Complexes of Bioactive Ligands with Superoxide Dismutase Activity
Khalid, H., Hanif, M., Hashmi, M., Mahmood, T., Ayub, K., & Monim-ul-Mehboob, M. (2013) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/13895575113136660092 · Cited by 48
Wang, Z., Qian, H., Yiu, S., Sun, J., & Zhu, G. (2013) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2013.10.017 · Cited by 47
Patra, M., Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Angewandte Chemie · doi:10.1002/ange.201510551 · Cited by 43
Webb, M. I., & Walsby, C. J. (2015) · Dalton Transactions · doi:10.1039/c5dt02021b · Cited by 41
Yano, S., Ohi, H., Ashizaki, M., Obata, M., Mikata, Y., Tanaka, R., Nishioka, T., Kinoshita, I., Sugai, Y., Okura, I., et al. (2012) · Chemistry & Biodiversity · doi:10.1002/cbdv.201100426 · Cited by 39
Joo, H. K., Lee, Y. R., Kang, G., Choi, S., Kim, C., Ryoo, S., Park, J. B., & Jeon, B. H. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0165 · Cited by 33
Mi, Q., Ma, Y., Gao, X., Liu, R., Liu, P., Mi, Y. M., Fu, X., & Gao, Q. (2015) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2015.1114972 · Cited by 29
THE SCOPE OF METAL COMPLEXES IN DRUG DESIGN - A REVIEW
Pattan, S. R., Pawar, S. B., Vetal, S. S., Gharate, U. D., & Bhawar, S. B. (2012) · INDIAN DRUGS · doi:10.53879/id.49.11.p0005 · Cited by 24
Koubková, L., Vyzula, R., Karban, J., Pinkas, J., Ondroušková, E., Vojtěšek, B., & Hrstka, R. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0274-y · Cited by 13
Cited by
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Nanoparticles in Clinical Translation for Cancer Therapy
Mundekkad, D., & Cho, W. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031685 · Cited by 305
Metadata
- Authors
- Ndagi, U., Mhlongo, N., & Soliman, M.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-03
- Volume
- Volume11
- Pages
- 599-616
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2591580144
- Cited by
- 935
- References
- 63
- FWCI
- 32.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.